Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OspA-MATD conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- Lochhead Scientific
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
The OspA-MATD conjugate vaccine is a preclinical-stage vaccine candidate for the prevention of Lyme disease, developed by Lochhead Scientific in partnership with the Medical College of Wisconsin. The vaccine utilizes a conjugate design that pairs lipidated *Borrelia burgdorferi* outer surface protein A (OspA) as a B-cell immunogen with the methyl-accepting transducer domain (MATD) of the chemotaxis protein Mcp4 as a T-cell immunogen. This approach is intended to elicit high-affinity, long-lasting protective antibodies by stimulating robust T cell-dependent germinal center responses, addressing the durability issues observed in earlier OspA-based vaccines. The Mcp4 MATD component was identified as an immunodominant CD4+ T cell antigen through immunopeptidomics, providing the necessary T-cell help to enhance the immune response against the *Borrelia burgdorferi* pathogen.
- Other names
- OspA-Mcp4 MATDOspA-Mcp-4 MATDOspA-Mcp 4 MATDOspA-Mcp4 MATD Conjugate VaccineOspA-Mcp-4 MATD Conjugate VaccineOspA-Mcp 4 MATD Conjugate Vaccine
02
Targets
CCL24 (Chemokine (C-C motif) ligand 24)OspA (Outer surface protein A)
Beyond the preview
Go deeper on OspA-MATD conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OspA-MATD conjugate vaccine.